Received Mar 3, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | W1A102M | OT / LA |
inappropriate use due to the administration of an expired dose of IPOL to a patient with no reported adverse event; Initial information received on 25-Feb-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 52 years old female patient as inappropriate use due to the administration of an expired dose of IPV (VERO) [IPOL] to a patient with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included Hepatitis a vaccine inact, Hepatitis b vaccine rHBsAg (yeast) (Twinrix); Yellow fever vaccine (Yellow fever vaccine); and Typhoid vaccine (Typhoid) for Immunisation. On 24-Feb-2025, the patient received IPV (VERO) Suspension for injection dose 0.5 ml 1x(once) (strength-standard) lot W1A102M expiry-10-Feb-2025 via intramuscular route in the left deltoid for immunization, inappropriate use due to the administration of an expired dose of ipol to a patient with no reported adverse event (expired product administered) (latency same day). Action take: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.
Twinrix; Yellow fever vaccine; Typhoid